When former DuPont CEO Ellen Kullman was at the helm, DuPont had been keen on building its industrial biosciences business unit as a global powerhouse as it shifted its strategy in expanding this business with the acquisition of Danisco for $7 billion back in 2011.

Enzymes, bioactive solutions, biomaterials, and biorefining products were the key segments to drive growth.  However, this strategy has changed with the merger of Dow Chemical and DuPont in 2015.  The merger is finally reaching its conclusion and DowDuPont announced during its recent first quarter earnings call that its biomaterials assets and R&D will soon be part of a non-core segment as the company considers its options including potential sale or spin-off.

More on this story will be published on this month’s Tecnon OrbiChem Biomaterials newsletter.